Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
122.96
-7.38 (-5.66%)
At close: Nov 5, 2026, 4:00 PM EST
114.40
-8.56 (-6.96%)
After-hours: Nov 5, 2026, 7:55 PM EST
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Halozyme Therapeutics stock has a consensus rating of "Buy" and an average price target of $108.89. The average 1-year stock price forecast is 11.44% lower than the current stock price, while the lowest is $79 (-35.75%) and the highest is $130 (+5.73%).
Price Target: $108.89 (-11.44%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Reiterates $78 → $79 | Hold | Reiterates | $78 → $79 | -35.75% | Nov 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $130 | Buy | Maintains | $130 | +5.73% | Nov 3, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $105 → $130 | Buy | Reiterates | $105 → $130 | +5.73% | Oct 13, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $110 | Buy | Maintains | $110 | -10.54% | Oct 8, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $93 → $105 | Buy | Reiterates | $93 → $105 | -14.61% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
1.88B
from 1.40B
Increased by 34.73%
Revenue Next Year
2.10B
from 1.88B
Increased by 11.71%
EPS This Year
8.84
from 4.15
Increased by 113.05%
EPS Next Year
10.69
from 8.84
Increased by 20.95%
EPS and Forward PE are based on non-GAAP adjusted numbers.